Bridgewater Associates holds over $142 million worth of Bristol-Myers Squibb shares.

The entities involved

• Bristol-Myers Squibb →

  American pharmaceutical company

  • Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
  • FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09
• Bridgewater Associates →

  asset manager

  • Patrick Gorman's professional profile includes roles as EVP at Booz Allen Hamilton, CSO at Bridgewater Associates, and his academic background from George Washington University.Thu 10:15

Related events

• Analysts raised price targets on Bristol-Myers Squibb shares.Aug 26
• Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.Aug 3
• Manufacturers Life Insurance Company reduced its share position in Bristol-Myers Squibb.Sep 12
• Bristol-Myers Squibb has taken ownership of Celgene's drug.Jun 7